Tag: BIO TECH

Kura Oncology, Inc. (Nasdaq: KURA) has reported preliminary clinical data from the first 20 patients in a Phase 1 dose-escalation trial of the company’s potent… [Read More]

Clinical stage pharmaceutical company, Essa Pharma (Nasdaq: EPIX), has presented updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide… [Read More]

Nexalin Technology (Nasdaq: NXL) has been awarded a key patent relating to the company’s non-invasive, frequency-based deep brain stimulation device by the United States Patent… [Read More]

Shares in Palisade Bio (Nasdaq: PALI) rose by more than 100% in intraday trading on Monday after the company announced positive preclinical data from a… [Read More]

 60 Degrees Pharmaceuticals (Nasdaq: SXTP) will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S. following a Type… [Read More]

Incannex Healthcare (Nasdaq: IXHL) has completed dosing of 72 participants in a Phase 2 clinical study evaluating a psilocybin treatment program for patients with generalized… [Read More]

AIM ImmunoTech (Nasdaq: AIM) has enrolled the first subject in a Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor… [Read More]

Cybin Inc. (NYSE American: CYBN) has been granted FDA clearance for its investigational new drug (IND) application for CYB004, its proprietary deuterated dimethyltryptamine (DMT) molecule… [Read More]

Shares in Sagimet Biosciences Inc. (Nasdaq: SGMT) soared 170% on Monday after the biopharmaceutical company announced positive topline results from its Phase 2b FASCINATE-2 clinical… [Read More]

Clinical stage biotechnology company, Vaxart, Inc. (Nasdaq: VXRT), has been awarded  $9.27 million by the United States Biomedical Advanced Research and Development Authority (BARDA) to… [Read More]